Current management of gastrointestinal carcinoid tumors

被引:73
作者
Woodside, KJ [1 ]
Townsend, CM [1 ]
Evers, BM [1 ]
机构
[1] Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA
关键词
carcinoid tumor; neuroendocrine tumor; carcinoid syndrome; gastrointestinal tract; somatostatin; review;
D O I
10.1016/j.gassur.2004.04.010
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Gastrointestinal carcinoid tumors are rare neuroendocrine tumors arising from the embryologic primitive gut. Depending on the location in the gastrointestinal tract, these tumors may secrete a variety of hormonally active substances. However, many of these tumors are found incidentally, or the diagnosis is made postoperatively. Also, there is a significant incidence of multicentric carcinoid tumors and synchronous noncarcinoid malignancies in these patients. Treatment is usually based on the size of the tumor. Surgical resection remains the cornerstone of therapy. For advanced metastatic disease, somatostatin analog therapy and surgical debulking provide the best symptomatic relief and may improve survival. Recent studies have demonstrated a benefit from radiolabeled somatostatin analogs for carcinoid tumor localization. In contrast, radiolabeled somatostatin analogs have shown little therapeutic benefit. Future directions include somatostatin receptor profiling of carcinoid tumors, with somatostatin analog therapy targeting the specific receptors. (C) 2004 The Society for Surgery of the Alimentary Tract.
引用
收藏
页码:742 / 756
页数:15
相关论文
共 144 条
[1]
CLINICAL EFFICACY OF OCTREOTIDE SCINTIGRAPHY IN PATIENTS WITH MIDGUT CARCINOID-TUMORS AND EVALUATION OF INTRAOPERATIVE SCINTILLATION DETECTION [J].
AHLMAN, H ;
WANGBERG, B ;
TISELL, LE ;
NILSSON, O ;
FJALLING, M ;
FORSSELLARONSSON, E .
BRITISH JOURNAL OF SURGERY, 1994, 81 (08) :1144-1149
[2]
ALUMETS J, 1981, CANCER-AM CANCER SOC, V48, P2409, DOI 10.1002/1097-0142(19811201)48:11<2409::AID-CNCR2820481112>3.0.CO
[3]
2-R
[4]
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours [J].
Aparicio, T ;
Ducreux, M ;
Baudin, E ;
Sabourin, JC ;
De Baere, T ;
Mitry, E ;
Schlumberger, M ;
Rougier, P .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (08) :1014-1019
[5]
IMMUNOHISTOLOGICAL LOCALIZATION OF GROWTH HORMONE-RELEASING HORMONE IN HUMAN-TUMORS [J].
ASA, SL ;
KOVACS, K ;
THORNER, MO ;
LEONG, DA ;
RIVIER, J ;
VALE, W .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1985, 60 (03) :423-427
[6]
BALLANTYNE GH, 1992, CANCER, V69, P2400, DOI 10.1002/1097-0142(19920515)69:10<2400::AID-CNCR2820691003>3.0.CO
[7]
2-Z
[8]
Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67 [J].
Belhocine, T ;
Foidart, J ;
Rigo, P ;
Najjar, F ;
Thiry, A ;
Quatresooz, P ;
Hustinx, R .
NUCLEAR MEDICINE COMMUNICATIONS, 2002, 23 (08) :727-734
[9]
Benevento A, 1998, SEMIN SURG ONCOL, V15, P239, DOI 10.1002/(SICI)1098-2388(199812)15:4<239::AID-SSU11>3.0.CO
[10]
2-4